Enanta Pharmaceuticals (NASDAQ:ENTA) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA - Free Report) from a hold rating to a sell rating in a research note published on Saturday.

Separately, JMP Securities upped their target price on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the stock a "market outperform" rating in a report on Tuesday, June 3rd. Two research analysts have rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

Enanta Pharmaceuticals Stock Up 1.2%

ENTA traded up $0.09 during trading hours on Friday, reaching $7.50. 243,932 shares of the company's stock traded hands, compared to its average volume of 285,804. The firm has a 50-day moving average price of $5.80 and a 200 day moving average price of $6.15. Enanta Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $17.24. The firm has a market capitalization of $160.33 million, a PE ratio of -1.52 and a beta of 0.76.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. The firm had revenue of $14.93 million during the quarter, compared to analysts' expectations of $15.96 million. Equities analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE acquired a new position in Enanta Pharmaceuticals during the 1st quarter valued at about $36,000. Tower Research Capital LLC TRC increased its position in Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after buying an additional 2,274 shares in the last quarter. GAMMA Investing LLC acquired a new position in shares of Enanta Pharmaceuticals in the first quarter valued at about $40,000. Intech Investment Management LLC acquired a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $58,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $66,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.